Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pfizer Links Up For Tb R&D In China

by Michael McCoy
April 12, 2010 | A version of this story appeared in Volume 88, Issue 15

Pfizer will work with MicuRx Pharmaceuticals and Cumencor Pharmaceuticals to discover treatments for multi-drug-resistant tuberculosis. Under the deal, Pfizer will make an upfront payment and provide funding for discovery and preclinical development of novel antibiotics. All research will be conducted at Shanghai’s Zhangjiang Hi-Tech Park, where MicuRx operates labs. Based in Hayward, Calif., MicuRx was formed by two scientists from Vicuron Pharmaceuticals, which Pfizer acquired in 2005. Cumencor is a China-based biotech firm applying MicuRx’s anti-infective discovery techniques.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.